ATS 2019 Virtual Final Program

P461 Association Between Clinicopathologic Characteristics and BRAFV600E Expression in Chinese Patients with Langerhans Cell Histiocytosis/ H. Huang, T. Lu, S. Li, Y. Sun, R. Feng, Z. Xu, Beijing, China, p.A1422 Facilitator : S.Y. El-Chemaly, MD, MPH, Boston, MA P462 Pulmonary Langerhans Cell Histiocytosis in Adults/ E. Radzikowska, K. Blasinska-Przerwa, M. Jeskiewicz-Kopij, R. Langfort, M. Szolkowska, K. Modrzewska, I. Bestry, M. Zaleska, J. Szopinski, E. Wiatr, K. Roszkowski, Warsaw, Poland, p.A1423 P463 Relationship Between Menopause and Development of Spontaneous Pneumothorax in Females with Lymphangioleiomyomatosis/ Z.G. Swank, E.J.-A. Kopras, N. Gupta, Cincinnati, OH, p.A1424 P464 Proteomic Profiling of Serum Exosomes to Identify Novel Biomarkers for Lymphangioleiomyomatosis/ T. Takimoto, Y. Takeda, T. Shiromizu, R. Narumi, T. Koba, M. Kuroyama, H. Kida, M. Hirose, Y. Inoue, T. Tomonaga, A. Kumanogoh, Sakai, Japan, p.A1425 P465 Delineating Novel mTOR-Independent Signaling Pathways for Lymphangioleiomyomatosis and Tuberous Sclerosis Therapy/ U.J. Unachukwu, X. Ma, J.M. D’Armiento, New York, NY, p.A1426 P466 Targeting AKT as a Therapeutic Intervention in Treatment of LAM/ K. Medepalli, S. Purdon, R. Choi, P. Catanuto, D.J. Kwiatkowski, S. Elliot, M.K. Glassberg Csete, Miami, FL, p.A1427 P467 Dysregulation of Sphingolipid Metabolism in Pulmonary Lymphangioleiomyomatosis (LAM)/ J.J. Yu, X. Liu, C. Li, A.R. Osterburg, N. Gupta, K.A. Wikenheiser-Brokamp, M.T. Borchers, J.C. Woods, F.X. McCormack, X. Zhao, M. Soleimani, K. Setchell, Cincinnati, OH, p.A1428 CLINICAL THEMATIC POSTER SESSION A37 CONNECTIVE TISSUE DISEASE-INTERSTITIAL LUNG DISEASE 9:15 a.m. - 4:15 p.m. KBHCCD Area B (Hall F, Level 2) Viewing: Posters will be on display for entire session. Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators. Facilitator : D. Assayag, MD, CM, Montreal, Canada P176 Frailty Measurements in Systemic Sclerosis Differ from Other Fibrotic Interstitial Lung Diseases/ S. Bhorade, R. Jablonski, J. Lee, M. Masihi, A. Ansari, R. Tomic, J.E. Dematte, Chicago, IL, p.A1429 P177 Nailfold Capillaroscopy Findings in ILD Patients: Results from a Single Centre Investigation/ F. Kuehner, O. Sander, E. Boerner, T. Wessendorf, U. Costabel, F. Bonella, Luzern, Switzerland, p.A1430 P178 Diverse Clinical Features of Interstitial Lung Disease in Patients with the Anti-SSA-52 kD Myositis-Associated Autoantibody/ A. Sclafani, E. Miloslavsky, A. Sharma, S. Montesi, Boston, MA, p.A1431 P179 Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease/ S. Matson, D. Dvorkin, A. Fischer, N. Achtar-Zadeh, P.J. Wolters, J.S. Lee, Aurora, CO, p.A1432 P180 Combined Rheumatology/ILD Service: How Successful It Is? A 2 Years’ Experience at a Large Acute NHS Trust in West Midlands/ P. Chohan, T. Sheeran, A. Fahim, Wolverhampton, United Kingdom, p.A1433 P181 Combined Pulmonary and Rheumatology Clinics Improve the Care of Patients with Interstitial Lung Diseases/ K. Rawal, I. Azuelos, C. Pineau, D. Assayag, Montreal, Canada, p.A1434 P182 Predictors for the Development of Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) - Data from the German SSc-Network/ M. Kreuter, F. Bonella, N. Blank, E. Siegert, J. Henes, M. Worm, C. Sunderkoetter, M. Schmalzing, A. Kreuter, C. Günther, L. Susok, G. Zeidler, I. Kötter, U. Müller-Ladner, T. Krieg, A. Juche, T. Schmeiser, G. Riemekasten, E. Aberer, N. Gaebelein-Wissing, J.H. W. Distler, M. Sardy, C. Pfeiffer, K. Kuhr, H. Lorenz, P. Moinzadeh, N. Hunzelmann, Heidelberg, Germany, P.A1435 P183 Prognostic Role of Blood KL-6 in Rheumatoid Arthritis-Associated Interstitial Lung Disease/ H. Kim, K.H. Choi, J. Jacob, J.W. Song, Seoul, Korea, Republic of, p.A1436 P184 Prognostic Factors of Clinical Evolution in Patients with Antisynthetase Syndrome Treated with Methotrexate, Leflunomide and Prednisone/ J.G. Mejia Hurtado, M. Mejia, H. Mateos-Toledo, I. Buendía-Roldan, G. Pérez-Rubio, R. Falfan-Valencia, E. Ambrocio-Ortiz, J. Rojas-Serrano, Mexico City, Mexico, p.A1437 P185 Prevalence and Diagnostic Implications of Myositis-Specific Antibodies in Interstitial Lung Disease/ J. Graham, J.V. Pugashetti, R.W. Harper, B.M. Morrissey, J. Oldham, Sacramento, CA, p.A1438 Facilitator : T. Luckhardt, MD, Birmingham, AL P186 The Place of Respiratory Manifestations During Scleroderma in Dakar: A Multicentric Study/ F.B.R. Mbaye, K. Thiam, M.F. Cissé, Y. Dia Kane, N.O. Touré, Dakar, Senegal, p.A1439 P187 Characterization of Airway Disease in Rheumatoid Arthritis/ M.L. Sabbag, C. de Assis Molina, M. Sawamura, K. Bonfiglioli, F.E. Arimura, R.A. Athanazio, C.R.R. Carvalho, R.A. Kairalla, L. Kawano-Dourado, Sao Paulo, Brazil, p.A1440 P188 Differences in Cytokine Profiles Between Antisynthetase Syndrome and MDA-5-Associated Dermatomyositis/ T. Takada, A. Aoki, K. Ohashi, Y. Kimura, M. Hayashi, T. Kikuchi, S. Sato, Minami-Uonuma, Japan, p.A1441 P189 Are the Autoantibodies Associated with the Distinctive Clinical Characteristics in Interstitial Pneumonia Patients with Systemic Sclerosis?/ R. Togawa, Y. Tanino, T. Nikaido, Y. Sato, T. Kawamata, M. Saito, N. Watanabe, M. Rikimaru, T. Umeda, Y. Suzuki, M. Uematsu, H. Minemura, A. Fukuhara, S. Sato, J. Saito, K. Kanazawa, Y. Shibata, Fukushima, Japan, p.A1442 ATS 2019 • Dallas, TX 52 SUNDAY • MAY 19